Pharsight

Drugs that contain Dexlansoprazole

1. Dexilant patents expiration

DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9145389 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US6462058 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US7285668 TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Jun, 2020

(3 years ago)

US6939971 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US7285668

(Pediatric)

TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Dec, 2020

(3 years ago)

US6462058

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6939971

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US8722084 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(7 months ago)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(7 months ago)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month ago)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month ago)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 7 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 7 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(1 year, 9 months from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(2 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation
Aug, 2026

(2 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(2 years from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(2 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(2 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(3 years from now)

US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(5 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(6 years from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
New Patient Population(NPP) Jul 08, 2019
Pediatric Exclusivity(PED) Jul 30, 2012

Market Authorisation Date: 30 January, 2009

Treatment: Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months; Treatment of heartburn associated with non-erosive gastroesophagea...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

2. Dexilant Solutab patents expiration

DEXILANT SOLUTAB's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9145389 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US7285668 TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Jun, 2020

(3 years ago)

US6462058 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(1 year, 3 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7399485 TAKEDA PHARMS USA Rapidly Disintegrable solid preparation
May, 2018

(5 years ago)

US7399485

(Pediatric)

TAKEDA PHARMS USA Rapidly Disintegrable solid preparation
Nov, 2018

(5 years ago)

US7431942 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US6328994 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US6238994 TAKEDA PHARMS USA Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article
May, 2019

(5 years ago)

US7875292 TAKEDA PHARMS USA Orally disintegrable tablets
May, 2019

(5 years ago)

US7875292

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US6328994

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US7431942

(Pediatric)

TAKEDA PHARMS USA Orally disintegrable tablets
Nov, 2019

(4 years ago)

US6238994

(Pediatric)

TAKEDA PHARMS USA Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article
Nov, 2019

(4 years ago)

US6939971 TAKEDA PHARMS USA Benzimidazole compound crystal
Jun, 2020

(3 years ago)

US6939971

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US7285668

(Pediatric)

TAKEDA PHARMS USA Process for the crystallization of (R)- or (S)-lansoprazole
Dec, 2020

(3 years ago)

US6462058

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Dec, 2020

(3 years ago)

US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(9 months ago)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(7 months ago)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(a month ago)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 7 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 7 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(1 year, 9 months from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(2 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(3 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules
Jul, 2028

(4 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation
Mar, 2029

(4 years from now)

Market Authorisation Date: 26 January, 2016

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents